OhmBody: Dual-Pathway Auricular Neurostimulation Wearable for Menstrual Wellness

The first consumer wearable designed to simultaneously engage vagus and trigeminal nerve pathways through ear-based neurostimulation for drug-free menstrual comfort, with pilot studies showing 88% of participants experiencing greater comfort, 55% average reduction in blood loss, and 71% reporting emotional stability.

Presented By Our Partners

Menstrual discomfort affects an estimated 80% of women at some point during their reproductive years, with approximately 20% experiencing symptoms severe enough to interfere with daily activities. The primary mechanisms behind menstrual pain involve prostaglandin-mediated uterine contractions, inflammatory pathways, and autonomic nervous system dysregulation that amplifies pain perception and disrupts gastrointestinal, mood, and sleep function. A 2023 systematic review published in Pain by Hellman et al. examined the neurobiological mechanisms of primary dysmenorrhea, finding that central sensitization and altered autonomic nervous system function contribute to the severity and breadth of menstrual symptoms beyond localized uterine pain (DOI: 10.1097/j.pain.0000000000002808).

Auricular (ear-based) neurostimulation has emerged as a non-invasive approach to modulating autonomic nervous system function through the vagus nerve, which has branches accessible at the ear. A 2022 meta-analysis published in Bioelectronic Medicine by Farmer et al. evaluated transcutaneous auricular vagus nerve stimulation (taVNS) for pain management, finding significant reductions in pain intensity across multiple chronic pain conditions with a favorable safety profile (DOI: 10.1186/s42234-022-00094-0). OhmBody applies this neurostimulation approach specifically to menstrual wellness, representing the first consumer wearable designed to simultaneously engage two cranial nerve pathways for this purpose.

What Is OhmBody?

OhmBody is a wearable neurostimulation device that delivers gentle, targeted, non-invasive electrical stimulation to cranial nerve pathways accessible at the ear to support menstrual comfort, reduce heavy bleeding, and improve emotional stability during the menstrual cycle. The device consists of a small handheld control unit connected to a discreet earpiece that delivers stimulation to the vagus and trigeminal nerves around the ear.

OhmBody is the first consumer wearable designed to simultaneously engage two cranial nerve pathways. The vagus nerve, the longest cranial nerve, regulates parasympathetic (rest and recover) function throughout the body, including gut motility, heart rate, inflammatory responses, and pain modulation. The trigeminal nerve, the primary sensory nerve of the face, carries pain signals and modulates somatosensory processing. By targeting both pathways simultaneously, OhmBody aims to address the multi-system nature of menstrual discomfort: pain, gastrointestinal symptoms, mood dysregulation, and stress response.

The device is positioned as hormone-free and drug-free, providing a non-pharmacological alternative to NSAIDs (ibuprofen, naproxen), hormonal contraceptives, and other pharmaceutical approaches to menstrual symptom management. The approach is informed by neuroscience research exploring how nervous system pathways relate to the menstrual experience across comfort, stress response, digestion, mood, sleep, and energy dimensions.

OhmBody was showcased at CES 2026, named a finalist for Best Wellness Tech at CES 2026, and received a nomination as a Finalist in the Edison Awards’ Women’s Health and Reproductive Innovations category.

The Science Behind Auricular Neurostimulation

The ear is a unique anatomical site for non-invasive nerve stimulation because both the vagus nerve (through its auricular branch, the Arnold’s nerve) and the trigeminal nerve have sensory territories in the external ear. This means gentle electrical stimulation applied to specific ear locations can activate these cranial nerves without surgery, needles, or systemic drug administration.

Vagus nerve stimulation (VNS) has been used therapeutically for decades, primarily through implanted devices for epilepsy and treatment-resistant depression. Transcutaneous auricular VNS (taVNS) emerged as a non-invasive alternative that accesses the vagal pathway through the ear. Research has demonstrated that taVNS can reduce inflammatory markers, modulate pain processing, improve heart rate variability (indicating enhanced parasympathetic tone), and influence mood regulation through activation of brainstem nuclei that project to cortical and subcortical regions involved in emotion and pain processing.

The relevance to menstrual health lies in the autonomic nervous system’s role in regulating uterine blood flow, inflammatory responses, pain perception, and the gastrointestinal symptoms that frequently accompany menstruation. Prostaglandins, the primary drivers of menstrual cramping, trigger uterine smooth muscle contractions and also activate afferent pain fibers. By modulating the autonomic balance toward parasympathetic predominance, vagal stimulation may reduce the amplification of pain signals and the inflammatory cascade that drives symptom severity.

The trigeminal nerve pathway adds a second modulation channel. Trigeminal stimulation has been studied primarily for migraine prevention, where external trigeminal nerve stimulation (using forehead-based devices like Cefaly) has received FDA clearance. The trigeminal nerve’s role in somatosensory processing and pain gating makes it a relevant target for multi-system pain conditions that involve central sensitization.

Combining vagal and trigeminal stimulation represents a novel dual-pathway approach that has not been extensively studied for menstrual applications specifically. OhmBody’s pilot data, while promising, represents early-stage evidence that would benefit from larger, more rigorous clinical trials.

What OhmBody Does Well

The drug-free and hormone-free mechanism of action is OhmBody’s most important differentiator. Many women cannot or prefer not to use hormonal contraceptives for menstrual symptom management due to side effects (weight changes, mood alterations, cardiovascular risks), contraindications, or personal preference. NSAIDs carry gastrointestinal risks with regular use. OhmBody provides an alternative modality that works through the nervous system rather than through pharmacological pathways.

The pilot study results, while preliminary, are encouraging. An 88% rate of participants experiencing greater menstrual comfort, a 55% average reduction in menstrual blood loss, and 71% reporting emotional stability suggest clinically meaningful effects across multiple symptom dimensions. The reduction in heavy menstrual bleeding is particularly notable, as heavy menstrual bleeding (menorrhagia) is a distinct clinical condition that affects quality of life and can lead to iron deficiency anemia.

The multi-symptom approach addresses the reality that menstrual discomfort is rarely limited to pain alone. The combination of cramping, bloating, gastrointestinal disturbance, mood changes, fatigue, and sleep disruption reflects the systemic nature of menstrual physiology, and a neuromodulation approach that targets multiple symptom domains through autonomic pathways may be more comprehensive than single-mechanism treatments.

The earpiece form factor is discreet. Unlike abdominal TENS units or heating pads that limit mobility and are visible, an earpiece can be worn during daily activities, at work, and in social settings without drawing attention.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The CES 2026 Best Wellness Tech finalist recognition and Edison Awards nomination provide third-party validation of the device’s innovation quality.

Pricing, Access, and Practical Realities

The OhmBody starter kit is priced at $559, available through the company’s website (ohmbody.com). The kit includes the control unit and earpiece. Replacement and accessory pricing have not been extensively detailed.

For comparison, non-pharmacological menstrual pain management alternatives include TENS units ($25 to $200, applied to the abdomen), prescription neuromodulation devices for pain (Cefaly for migraine: approximately $400), and heated wearable pads ($30 to $80). OhmBody is priced at a premium relative to these alternatives, reflecting its targeted neuroscience-informed approach and dual-pathway stimulation capability.

Monthly pharmaceutical costs for menstrual symptom management (hormonal contraceptives: $0 to $50/month; NSAIDs: $5 to $15/month) are lower per-month but accumulate over years and carry their own side effect profiles. Over a five-year period, OhmBody’s one-time $559 cost may compare favorably to cumulative pharmaceutical spending for some users.

The device requires consistent use during menstrual periods to achieve the reported benefits. Users should follow the manufacturer’s recommended stimulation protocols for duration and frequency. The treatment sessions are delivered through the earpiece, meaning users must wear the device during active stimulation periods.

Who It Is Best For

OhmBody is best suited for women who experience moderate to severe menstrual discomfort and want a drug-free, hormone-free management approach. Women who have experienced side effects from hormonal contraceptives or who have contraindications to hormonal therapy represent a primary audience.

Women with heavy menstrual bleeding (menorrhagia) who want to explore non-pharmacological options for reducing flow may benefit from the 55% average blood loss reduction reported in pilot studies, though they should discuss this approach with their healthcare provider alongside conventional management.

Women who experience multi-system menstrual symptoms (cramping plus mood changes plus GI symptoms plus sleep disruption) may find the autonomic neuromodulation approach more comprehensive than single-symptom treatments like heating pads (pain only) or anti-spasmodics (cramping only).

The device is less suited for women whose menstrual symptoms are well-controlled with existing approaches, for those who find ear-based devices uncomfortable, or for women with severe menstrual conditions (endometriosis, adenomyosis) that require medical treatment beyond symptom management.

How It Compares

Against TENS units for menstrual pain ($25 to $200), OhmBody offers a different stimulation target (cranial nerves via the ear versus peripheral nerve stimulation via abdominal electrodes) and a broader symptom target (pain, bleeding, mood, GI symptoms versus primarily pain). TENS is cheaper, well-validated for pain, and available over the counter.

Against hormonal contraceptives (various pricing), OhmBody offers a hormone-free alternative that avoids the systemic effects of hormonal therapy. Hormonal approaches are well-validated and can reduce menstrual symptoms effectively but carry side effect profiles that some women find unacceptable.

Against the Peri wearable ($449), which tracks perimenopause symptoms, OhmBody is a treatment device rather than a monitoring device. Peri quantifies symptoms; OhmBody aims to reduce them. The two devices serve different purposes within women’s health technology.

No other consumer device combines dual-pathway auricular neurostimulation (vagus plus trigeminal) specifically for menstrual wellness, making OhmBody unique in its approach.

Limitations and Open Questions

The pilot study data, while promising, involves small sample sizes that limit generalizability. The reported statistics (88% comfort improvement, 55% blood loss reduction, 71% emotional stability) need replication in larger, randomized, sham-controlled trials with diverse populations to establish robust efficacy evidence.

The mechanism by which auricular neurostimulation reduces menstrual blood loss is not fully elucidated. While autonomic modulation of uterine blood flow is a plausible pathway, the specific mechanism deserves further investigation and would strengthen the scientific foundation for this claim.

The $559 price point is a significant investment for a device that treats a recurring but periodic condition. Users should evaluate whether the severity and frequency of their symptoms justify this investment compared to less expensive alternatives.

Long-term efficacy data is not available. Whether the benefits persist with continued use over months and years, or whether tolerance develops, is unknown. Similarly, whether benefits persist after discontinuation of the device has not been studied.

The device is sold as a consumer wellness product, not as an FDA-cleared medical device. This means the menstrual symptom reduction claims have not been evaluated by the FDA. Women with clinically significant menstrual disorders should consult healthcare providers rather than relying solely on a consumer device.

What This Means for Your Health

Menstrual health represents a domain where conventional treatment options (hormones and NSAIDs) have remained largely unchanged for decades despite significant unmet patient need. Neuromodulation offers a fundamentally different therapeutic approach that works through the body’s own regulatory systems rather than pharmacologically overriding them.

Within Healthcare Discovery‘s Five Pillars framework, menstrual wellness intersects with Movement (exercise capacity during menstruation), Sleep (menstrual-related sleep disruption), Nutrition (iron depletion from heavy bleeding, dietary factors that influence inflammation), Breathwork (vagal tone and stress regulation), and Mindset (the emotional and psychological impact of menstrual symptoms on daily functioning and quality of life).

OhmBody’s vagus nerve stimulation approach is particularly interesting from a longevity perspective because vagal tone is increasingly recognized as a biomarker of overall health resilience. The vagus nerve mediates the anti-inflammatory reflex, regulates cardiovascular function, and influences gut-brain axis communication. Technologies that enhance vagal function may have benefits extending beyond their primary indication.

The emergence of purpose-built women’s health devices like OhmBody and Peri signals a maturation of the femtech sector from period-tracking apps to physiologically active wearables that address women’s health needs with the same technological sophistication applied to fitness and recovery tracking.

Frequently Asked Questions

What is OhmBody?
OhmBody is a wearable neurostimulation device that delivers gentle electrical stimulation to the vagus and trigeminal nerves through an earpiece to provide drug-free, hormone-free menstrual comfort. It is the first consumer device to simultaneously engage two cranial nerve pathways for menstrual wellness.

How much does OhmBody cost?
The OhmBody starter kit is priced at $559, available through ohmbody.com. No subscription is required.

Does OhmBody actually work?
In pilot studies, 88% of participants reported greater menstrual comfort, with a 55% average reduction in menstrual blood loss and 71% reporting emotional stability. These results are promising but come from small early studies; larger clinical trials are needed for definitive efficacy evidence.

Is OhmBody FDA approved?
OhmBody is sold as a consumer wellness device, not as an FDA-cleared medical device. It was named a CES 2026 Best Wellness Tech finalist and an Edison Awards finalist in Women’s Health and Reproductive Innovations.

How is OhmBody different from a TENS unit?
TENS units deliver electrical stimulation to peripheral nerves through abdominal electrodes, primarily targeting pain. OhmBody stimulates cranial nerves (vagus and trigeminal) through the ear, targeting multiple symptom dimensions including pain, bleeding, mood, gastrointestinal symptoms, and stress response through autonomic nervous system modulation.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.